Los Angeles Capital Management
INBX icon

Los Angeles Capital Management’s Inhibrx INBX Stock Holding History

Los Angeles Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.59K Buy
98
+60
+158% +$4.45K ﹤0.01% 2050
2025
Q4 		$2.98K Buy
+38
New +$2.59K ﹤0.01% 2380

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Los Angeles Capital Management's INBX Position: Q1 2026 in Review

Los Angeles Capital Management increased its Inhibrx (INBX) stake by 158% in Q1 2026, buying an estimated $4.45K and bringing the position to 98 shares worth $6.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2050.

Los Angeles Capital Management first reported a position in INBX in Q4 2025 and has held it in 2 quarters since. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Los Angeles Capital Management held 98 shares of Inhibrx worth $6.59K as of Q1 2026.
  • Los Angeles Capital Management bought 60 Inhibrx shares in Q1 2026, an estimated $4.45K.
  • Inhibrx made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2050 holding.
  • Los Angeles Capital Management first reported a position in Inhibrx in Q4 2025 and has held it in 2 quarters since.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.